Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apthera Inc.

Division of Sellas Life Sciences Group Inc.
www.apthera.com

Latest From Apthera Inc.

Galena’s NeuVax Mops Up Circulating Breast Cancer Cells To Prevent Metastases

Median five-year data from the Phase I/II NeuVax trial released at ASCO this June showed that among node-positive patients 25.9% of the control had a recurrence, while metastases surfaced in only 5.6% of NeuVax patients. Final gold standard five-year data for all patients were released at the San Antonio Breast Cancer Symposium Dec. 5; Galena launched a Phase III trial in January 2012.

BioPharmaceutical Clinical Trials

GSK taps new MD Anderson institute in $335m OX40 antibody deal

The University of Texas MD Anderson Cancer Center is continuing its legacy of licensing oncology discoveries to pharmaceutical companies via a collaboration with GlaxoSmithKline through which the cancer center may earn more than $335 million in upfront and milestone payments plus royalties on sales of therapeutic antibodies that activate OX40 receptors on the surface of T cells to mount an immune system attack.

Cancer

Galena public offering raises $14.5M to support NeuVax studies

Galena Biopharma, a US oncology-focused company, said that it has closed on its underwritten public offering for gross proceeds of about $14.5 million. consisted of 9.75 million shares of its common stock at $1.50 per share,.

Cancer

Galena nets $11.6mn from common stock offering to support NeuVax studies

Galena Biopharma, a US firm focused on oncology, will net $11.6 million to advance its cancer immunotherapy NeuVax from the sale of 8.5 million shares of common stock at $1.50 per share in an offering set to close on 11 April.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sellas Life Sciences Group Inc.
  • Senior Management
  • Mark W Schwartz, PhD, Pres. & CEO
    Robert E Kennedy, CFO
  • Contact Info
  • Apthera Inc.
    Phone: (480) 348-9707
    8418 E. Shea Blvd.
    Ste. 100
    Scottsdale, AZ 85260
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register